文献速递血栓与止血

髂股静脉支架置入术后抗血栓管理:系统综述

Postinterventional antithrombotic management after venous stenting of the iliofemoral tract in acute and chronic thrombosis: A systematic review.
PubMed 文献 · J Thromb Haemost · 2021-01-05

该系统综述检索了PubMed、MEDLINE、EMBASE和Cochrane数据库,纳入64篇文章(含56项原始研究),评估急性或慢性血栓性病变行髂股静脉支架置入后抗血栓治疗的文献。术后1年平均一期通畅率为82.3%,2年降至73.3%;77%的研究以维生素K拮抗剂为基础治疗。仅2项研究直接评估抗血栓治疗对结局的影响,其对支架通畅性的作用仍不明确。

要点

  • 髂股静脉支架术后1年一期通畅率82.3%,2年降至73.3%。
  • 77%的研究使用维生素K拮抗剂,其中59%单用、18%联用抗血小板药。
  • 仅4%的研究直接评估抗血栓治疗对支架通畅性的影响。

核心结论

  • 现有文献数据有限且不充分,介入后抗血栓治疗对静脉支架通畅性的影响仍未知。
  • 需进一步临床研究明确抗血栓治疗在维持静脉支架长期通畅性中的作用。

研究设计与样本

  • 系统综述,检索PubMed、MEDLINE、EMBASE和Cochrane数据库。
  • 共识别277篇文章,最终纳入64篇(含56项原始研究)。
  • 纳入标准为急性或慢性血栓性病变行髂股静脉支架置入后接受抗血栓治疗的研究。

主要发现

  • 术后1年平均一期通畅率为82.3%,2年降至73.3%。
  • 56项研究中43项(77%)治疗以维生素K拮抗剂为基础,其中18%联用抗血小板药、59%未联用。
  • 仅2项研究(4%)直接评估抗血栓治疗对治疗结局的影响。

关键数值与推荐

  • 术后1年平均一期通畅率82.3%,2年73.3%。
  • 维生素K拮抗剂为基础的治疗占77%(43/56项研究),其中联用抗血小板药者占18%、未联用者占59%。
  • 直接评估抗血栓治疗对结局影响的研究仅占4%(2项)。

临床怎么用

  • 髂股静脉支架置入后抗血栓方案的选择目前缺乏直接证据支持。
  • 临床决策需权衡支架通畅性与血栓复发风险,期待更高质量研究指导。

局限性

  • 仅2项研究直接评估抗血栓治疗对结局的影响,数据有限且不充分。
  • 无法明确介入后抗血栓治疗对支架通畅性的作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Venous stenting has become a common treatment option for central deep venous outflow obstructions and postthrombotic syndrome. Following successful recanalization and stenting, stent patency is endangered by in-stent thrombosis and recurrent venous thromboembolism. Antithrombotic therapy might reduce patency loss. This systematic review summarizes the literature on antithrombotic therapy following (post)thrombotic venous stenting. A systematic PubMed, MEDLINE, EMBASE, and Cochrane search was performed for studies addressing antithrombotic therapy prescribed following venous stenting of the iliofemoral tract indicated by acute or chronic thrombotic pathology. A total of 277 articles was identified of which 64 (56 original studies) were selected. Overall, a mean primary patency rate of 82.3% was seen 1 year after the intervention, which decreased to 73.3% after 2 years. In the majority (43 of 56 studies, 77%), treatment was based on use of vitamin K antagonists, either with (18%) or without (59%) use of antiplatelet drugs. Only two studies (4%) directly assessed the effect of antithrombotic therapy on treatment outcomes. The impact of postinterventional antithrombotic therapy on stent patency remains unknown because of limited and insufficient data available in current literature. Further clinical research should more clearly address the role of antithrombotic therapy for preservation of long-term patency following venous stenting.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Notten P, Ten Cate H, Ten Cate-Hoek AJ, et al. Postinterventional antithrombotic management after venous stenting of the iliofemoral tract in acute and chronic thrombosis: A systematic review. J Thromb Haemost. 2021. PMID: 33249698. doi:10.1111/jth.15197

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。